Given that intracellular ADMA levels are mainly regulated by PRMT and DDAH, specific PRMT inhibitors or DDAH agonists might become novel therapeutic strategies to restore ADMA–NO and prevent hypertension. This evidence concerns the gene DDAH2 and Hypertension.